Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations

Growth Horm IGF Res. 2015 Oct;25(5):240-6. doi: 10.1016/j.ghir.2015.07.002. Epub 2015 Jul 11.

Abstract

Objective: The studies that have extensively evaluated the relation between adipokines and metabolic parameters in acromegaly treatment are quite discordant. We aimed to evaluate and correlate a set of selected adipokines, known to have a metabolic role, with the disease activity, metabolic status and treatment modalities.

Design: Data of 56 consecutive acromegalic patients (31 M and 25 F; aged 54 ± 12 years), admitted to the section of Endocrinology of the University of Palermo during the years 2005-2014, including 16 newly diagnosed untreated (ND), 21 during therapy with somatostatin analogues (SA), 12 with pegvisomant (PE) and 7 after surgical treatment (SU), grouped into uncontrolled (group A: No. 33) and controlled (group B: No. 23) were evaluated. Anthropometric and metabolic parameters, insulin sensitivity indexes, visceral adiposity index (VAI), leptin, soluble leptin receptor, adiponectin, visfatin, resistin, adipsin and non-esterified fatty acids (NEFAs) were assessed. In a subgroup of 21 subjects, the insulin sensitivity index (M value) derived from euglycemic clamp was calculated.

Results: Group A showed higher Homa-IR (p < 0.001), VAI (p < 0.001), triglycerides (p < 0.001), visfatin (p < 0.001), and NEFAs (p < 0.001) and lower ISI Matsuda (p < 0.001), M value (p < 0.001), HDL cholesterol (p < 0.001) and leptin (p < 0.001) than group B. ND patients showed higher VAI, triglycerides, Homa-IR, and visfatin and lower ISI Matsuda, M-value, and leptin compared to other groups (all p < 0.050), while no differences were found among SA, PE and SU patients. IGF-1 (p = 0.048), M-value (p = 0.0029) and VAI (p = 0.010) were independently associated with visfatin, while only ISI Matsuda (p = 0.019) was associated with leptin.

Conclusions: In acromegaly visfatin could be considered a useful index of disease activity and metabolic alterations, such as insulin resistance and adipose dysfunction, regardless of the type of treatment.

Keywords: Acromegaly; Adipokines; Growth hormone.

MeSH terms

  • Acromegaly / blood*
  • Acromegaly / pathology
  • Acromegaly / therapy
  • Adipokines / blood
  • Adiposity
  • Adult
  • Aged
  • Biomarkers / blood
  • Cholesterol, HDL / blood
  • Cross-Sectional Studies
  • Cytokines / blood*
  • Fatty Acids, Nonesterified / blood
  • Female
  • Humans
  • Insulin Resistance
  • Leptin / blood
  • Male
  • Middle Aged
  • Nicotinamide Phosphoribosyltransferase / blood*
  • Triglycerides / blood

Substances

  • Adipokines
  • Biomarkers
  • Cholesterol, HDL
  • Cytokines
  • Fatty Acids, Nonesterified
  • Leptin
  • Triglycerides
  • Nicotinamide Phosphoribosyltransferase
  • nicotinamide phosphoribosyltransferase, human